nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—ABCG2—Teniposide—lymphatic system cancer	0.126	0.246	CbGbCtD
Nilotinib—ABCG2—Mitoxantrone—lymphatic system cancer	0.0884	0.172	CbGbCtD
Nilotinib—ABCG2—Vincristine—lymphatic system cancer	0.0608	0.118	CbGbCtD
Nilotinib—CYP2C9—Teniposide—lymphatic system cancer	0.0469	0.0914	CbGbCtD
Nilotinib—ABCG2—Methotrexate—lymphatic system cancer	0.0368	0.0717	CbGbCtD
Nilotinib—ABCB1—Mitoxantrone—lymphatic system cancer	0.0319	0.062	CbGbCtD
Nilotinib—CYP3A4—Cytarabine—lymphatic system cancer	0.0277	0.054	CbGbCtD
Nilotinib—CYP3A4—Teniposide—lymphatic system cancer	0.0273	0.0531	CbGbCtD
Nilotinib—ABCB1—Vincristine—lymphatic system cancer	0.0219	0.0427	CbGbCtD
Nilotinib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0191	0.0372	CbGbCtD
Nilotinib—ABCB1—Methotrexate—lymphatic system cancer	0.0133	0.0259	CbGbCtD
Nilotinib—CYP3A4—Vincristine—lymphatic system cancer	0.0131	0.0256	CbGbCtD
Nilotinib—CSF1R—Differentiation Pathway—ALK—lymphatic system cancer	0.000907	0.165	CbGpPWpGaD
Nilotinib—Alopecia—Vincristine—lymphatic system cancer	0.000488	0.00102	CcSEcCtD
Nilotinib—Back pain—Carmustine—lymphatic system cancer	0.000488	0.00101	CcSEcCtD
Nilotinib—Discomfort—Bleomycin—lymphatic system cancer	0.000486	0.00101	CcSEcCtD
Nilotinib—Mental disorder—Vincristine—lymphatic system cancer	0.000484	0.00101	CcSEcCtD
Nilotinib—Chills—Mitoxantrone—lymphatic system cancer	0.000483	0.001	CcSEcCtD
Nilotinib—Ecchymosis—Methotrexate—lymphatic system cancer	0.000483	0.001	CcSEcCtD
Nilotinib—Neoplasm—Methotrexate—lymphatic system cancer	0.000483	0.001	CcSEcCtD
Nilotinib—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000483	0.001	CcSEcCtD
Nilotinib—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000481	0.001	CcSEcCtD
Nilotinib—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000478	0.000994	CcSEcCtD
Nilotinib—Alopecia—Mitoxantrone—lymphatic system cancer	0.000476	0.000989	CcSEcCtD
Nilotinib—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000475	0.000989	CcSEcCtD
Nilotinib—Confusional state—Bleomycin—lymphatic system cancer	0.000475	0.000988	CcSEcCtD
Nilotinib—Vision blurred—Carmustine—lymphatic system cancer	0.000475	0.000988	CcSEcCtD
Nilotinib—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000474	0.000985	CcSEcCtD
Nilotinib—Tremor—Carmustine—lymphatic system cancer	0.000472	0.000982	CcSEcCtD
Nilotinib—Oedema—Bleomycin—lymphatic system cancer	0.000471	0.00098	CcSEcCtD
Nilotinib—MAPK8—FoxO family signaling—BCL6—lymphatic system cancer	0.00047	0.0853	CbGpPWpGaD
Nilotinib—Erythema—Mitoxantrone—lymphatic system cancer	0.000469	0.000975	CcSEcCtD
Nilotinib—Infection—Bleomycin—lymphatic system cancer	0.000468	0.000974	CcSEcCtD
Nilotinib—Anaemia—Carmustine—lymphatic system cancer	0.000466	0.000969	CcSEcCtD
Nilotinib—Back pain—Vincristine—lymphatic system cancer	0.000465	0.000968	CcSEcCtD
Nilotinib—Vomiting—Teniposide—lymphatic system cancer	0.000465	0.000967	CcSEcCtD
Nilotinib—Sepsis—Methotrexate—lymphatic system cancer	0.000464	0.000964	CcSEcCtD
Nilotinib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000461	0.00096	CcSEcCtD
Nilotinib—Asthenia—Fludarabine—lymphatic system cancer	0.000461	0.000959	CcSEcCtD
Nilotinib—Rash—Teniposide—lymphatic system cancer	0.000461	0.000959	CcSEcCtD
Nilotinib—Dermatitis—Teniposide—lymphatic system cancer	0.000461	0.000958	CcSEcCtD
Nilotinib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000459	0.000954	CcSEcCtD
Nilotinib—Headache—Teniposide—lymphatic system cancer	0.000458	0.000953	CcSEcCtD
Nilotinib—Pruritus—Fludarabine—lymphatic system cancer	0.000455	0.000946	CcSEcCtD
Nilotinib—Back pain—Mitoxantrone—lymphatic system cancer	0.000453	0.000943	CcSEcCtD
Nilotinib—KIT—Differentiation Pathway—ALK—lymphatic system cancer	0.000453	0.0822	CbGpPWpGaD
Nilotinib—Leukopenia—Carmustine—lymphatic system cancer	0.000451	0.000938	CcSEcCtD
Nilotinib—Anorexia—Bleomycin—lymphatic system cancer	0.000449	0.000934	CcSEcCtD
Nilotinib—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000446	0.000927	CcSEcCtD
Nilotinib—Anaemia—Vincristine—lymphatic system cancer	0.000445	0.000925	CcSEcCtD
Nilotinib—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000442	0.000918	CcSEcCtD
Nilotinib—Photosensitivity—Methotrexate—lymphatic system cancer	0.000442	0.000918	CcSEcCtD
Nilotinib—Hypotension—Bleomycin—lymphatic system cancer	0.00044	0.000916	CcSEcCtD
Nilotinib—Diarrhoea—Fludarabine—lymphatic system cancer	0.00044	0.000915	CcSEcCtD
Nilotinib—Hypertension—Carmustine—lymphatic system cancer	0.000435	0.000905	CcSEcCtD
Nilotinib—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000435	0.000904	CcSEcCtD
Nilotinib—Nausea—Teniposide—lymphatic system cancer	0.000434	0.000903	CcSEcCtD
Nilotinib—Anaemia—Mitoxantrone—lymphatic system cancer	0.000433	0.000901	CcSEcCtD
Nilotinib—Vertigo—Vincristine—lymphatic system cancer	0.000432	0.000899	CcSEcCtD
Nilotinib—Leukopenia—Vincristine—lymphatic system cancer	0.000431	0.000896	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000429	0.000893	CcSEcCtD
Nilotinib—Chest pain—Carmustine—lymphatic system cancer	0.000429	0.000892	CcSEcCtD
Nilotinib—Myalgia—Carmustine—lymphatic system cancer	0.000429	0.000892	CcSEcCtD
Nilotinib—Anxiety—Carmustine—lymphatic system cancer	0.000428	0.000889	CcSEcCtD
Nilotinib—Paraesthesia—Bleomycin—lymphatic system cancer	0.000423	0.00088	CcSEcCtD
Nilotinib—Malaise—Mitoxantrone—lymphatic system cancer	0.000423	0.000879	CcSEcCtD
Nilotinib—Dyspnoea—Bleomycin—lymphatic system cancer	0.00042	0.000874	CcSEcCtD
Nilotinib—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00042	0.000872	CcSEcCtD
Nilotinib—Hypertension—Vincristine—lymphatic system cancer	0.000415	0.000864	CcSEcCtD
Nilotinib—Confusional state—Carmustine—lymphatic system cancer	0.000415	0.000863	CcSEcCtD
Nilotinib—Oedema—Carmustine—lymphatic system cancer	0.000411	0.000856	CcSEcCtD
Nilotinib—Decreased appetite—Bleomycin—lymphatic system cancer	0.00041	0.000852	CcSEcCtD
Nilotinib—Myalgia—Vincristine—lymphatic system cancer	0.00041	0.000852	CcSEcCtD
Nilotinib—Cough—Mitoxantrone—lymphatic system cancer	0.000409	0.00085	CcSEcCtD
Nilotinib—Infection—Carmustine—lymphatic system cancer	0.000409	0.00085	CcSEcCtD
Nilotinib—Vomiting—Fludarabine—lymphatic system cancer	0.000409	0.00085	CcSEcCtD
Nilotinib—Rash—Fludarabine—lymphatic system cancer	0.000405	0.000843	CcSEcCtD
Nilotinib—Dermatitis—Fludarabine—lymphatic system cancer	0.000405	0.000842	CcSEcCtD
Nilotinib—Hypertension—Mitoxantrone—lymphatic system cancer	0.000405	0.000841	CcSEcCtD
Nilotinib—Pain—Bleomycin—lymphatic system cancer	0.000403	0.000838	CcSEcCtD
Nilotinib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000403	0.000838	CcSEcCtD
Nilotinib—Headache—Fludarabine—lymphatic system cancer	0.000403	0.000837	CcSEcCtD
Nilotinib—Tachycardia—Carmustine—lymphatic system cancer	0.000402	0.000835	CcSEcCtD
Nilotinib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000399	0.00083	CcSEcCtD
Nilotinib—Myalgia—Mitoxantrone—lymphatic system cancer	0.000399	0.00083	CcSEcCtD
Nilotinib—Chest pain—Mitoxantrone—lymphatic system cancer	0.000399	0.00083	CcSEcCtD
Nilotinib—Anxiety—Mitoxantrone—lymphatic system cancer	0.000398	0.000827	CcSEcCtD
Nilotinib—Lethargy—Methotrexate—lymphatic system cancer	0.000396	0.000823	CcSEcCtD
Nilotinib—Discomfort—Mitoxantrone—lymphatic system cancer	0.000394	0.00082	CcSEcCtD
Nilotinib—Oedema—Vincristine—lymphatic system cancer	0.000393	0.000817	CcSEcCtD
Nilotinib—Anorexia—Carmustine—lymphatic system cancer	0.000392	0.000816	CcSEcCtD
Nilotinib—MAP4K1—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000392	0.071	CbGpPWpGaD
Nilotinib—Infection—Vincristine—lymphatic system cancer	0.00039	0.000811	CcSEcCtD
Nilotinib—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000388	0.000808	CcSEcCtD
Nilotinib—Confusional state—Mitoxantrone—lymphatic system cancer	0.000386	0.000802	CcSEcCtD
Nilotinib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000385	0.000801	CcSEcCtD
Nilotinib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000385	0.0008	CcSEcCtD
Nilotinib—Hypotension—Carmustine—lymphatic system cancer	0.000384	0.000799	CcSEcCtD
Nilotinib—Oedema—Mitoxantrone—lymphatic system cancer	0.000382	0.000795	CcSEcCtD
Nilotinib—Nausea—Fludarabine—lymphatic system cancer	0.000382	0.000794	CcSEcCtD
Nilotinib—Infection—Mitoxantrone—lymphatic system cancer	0.00038	0.00079	CcSEcCtD
Nilotinib—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00038	0.00079	CcSEcCtD
Nilotinib—Shock—Mitoxantrone—lymphatic system cancer	0.000376	0.000783	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000375	0.000779	CcSEcCtD
Nilotinib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000374	0.000779	CcSEcCtD
Nilotinib—Urticaria—Bleomycin—lymphatic system cancer	0.000374	0.000779	CcSEcCtD
Nilotinib—Anorexia—Vincristine—lymphatic system cancer	0.000374	0.000778	CcSEcCtD
Nilotinib—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000373	0.000776	CcSEcCtD
Nilotinib—Body temperature increased—Bleomycin—lymphatic system cancer	0.000373	0.000775	CcSEcCtD
Nilotinib—Insomnia—Carmustine—lymphatic system cancer	0.000372	0.000774	CcSEcCtD
Nilotinib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000372	0.000773	CcSEcCtD
Nilotinib—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00037	0.000769	CcSEcCtD
Nilotinib—Paraesthesia—Carmustine—lymphatic system cancer	0.000369	0.000768	CcSEcCtD
Nilotinib—Hypotension—Vincristine—lymphatic system cancer	0.000367	0.000763	CcSEcCtD
Nilotinib—Dyspnoea—Carmustine—lymphatic system cancer	0.000367	0.000763	CcSEcCtD
Nilotinib—Anorexia—Mitoxantrone—lymphatic system cancer	0.000365	0.000758	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000358	0.000744	CcSEcCtD
Nilotinib—Decreased appetite—Carmustine—lymphatic system cancer	0.000358	0.000744	CcSEcCtD
Nilotinib—Hypotension—Mitoxantrone—lymphatic system cancer	0.000357	0.000743	CcSEcCtD
Nilotinib—Insomnia—Vincristine—lymphatic system cancer	0.000355	0.000739	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000355	0.000739	CcSEcCtD
Nilotinib—Paraesthesia—Vincristine—lymphatic system cancer	0.000353	0.000733	CcSEcCtD
Nilotinib—Constipation—Carmustine—lymphatic system cancer	0.000352	0.000732	CcSEcCtD
Nilotinib—Pain—Carmustine—lymphatic system cancer	0.000352	0.000732	CcSEcCtD
Nilotinib—Breast disorder—Methotrexate—lymphatic system cancer	0.00035	0.000729	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000348	0.000725	CcSEcCtD
Nilotinib—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000347	0.000722	CcSEcCtD
Nilotinib—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000343	0.000714	CcSEcCtD
Nilotinib—Decreased appetite—Vincristine—lymphatic system cancer	0.000341	0.00071	CcSEcCtD
Nilotinib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000341	0.000709	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000339	0.000705	CcSEcCtD
Nilotinib—Feeling abnormal—Carmustine—lymphatic system cancer	0.000339	0.000705	CcSEcCtD
Nilotinib—Fatigue—Vincristine—lymphatic system cancer	0.000339	0.000704	CcSEcCtD
Nilotinib—Asthenia—Bleomycin—lymphatic system cancer	0.000338	0.000703	CcSEcCtD
Nilotinib—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000337	0.0007	CcSEcCtD
Nilotinib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000336	0.0007	CcSEcCtD
Nilotinib—Pain—Vincristine—lymphatic system cancer	0.000336	0.000698	CcSEcCtD
Nilotinib—Constipation—Vincristine—lymphatic system cancer	0.000336	0.000698	CcSEcCtD
Nilotinib—Pruritus—Bleomycin—lymphatic system cancer	0.000333	0.000693	CcSEcCtD
Nilotinib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000332	0.000691	CcSEcCtD
Nilotinib—Eosinophilia—Methotrexate—lymphatic system cancer	0.000332	0.00069	CcSEcCtD
Nilotinib—Fatigue—Mitoxantrone—lymphatic system cancer	0.00033	0.000686	CcSEcCtD
Nilotinib—Pancreatitis—Methotrexate—lymphatic system cancer	0.000329	0.000683	CcSEcCtD
Nilotinib—Constipation—Mitoxantrone—lymphatic system cancer	0.000327	0.00068	CcSEcCtD
Nilotinib—Pain—Mitoxantrone—lymphatic system cancer	0.000327	0.00068	CcSEcCtD
Nilotinib—Abdominal pain—Carmustine—lymphatic system cancer	0.000325	0.000676	CcSEcCtD
Nilotinib—Body temperature increased—Carmustine—lymphatic system cancer	0.000325	0.000676	CcSEcCtD
Nilotinib—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000321	0.000668	CcSEcCtD
Nilotinib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000321	0.000668	CcSEcCtD
Nilotinib—Pancytopenia—Methotrexate—lymphatic system cancer	0.000318	0.000662	CcSEcCtD
Nilotinib—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000315	0.000655	CcSEcCtD
Nilotinib—Dysuria—Methotrexate—lymphatic system cancer	0.000313	0.000652	CcSEcCtD
Nilotinib—Neutropenia—Methotrexate—lymphatic system cancer	0.000313	0.000652	CcSEcCtD
Nilotinib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000313	0.00065	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000311	0.000648	CcSEcCtD
Nilotinib—Abdominal pain—Vincristine—lymphatic system cancer	0.00031	0.000646	CcSEcCtD
Nilotinib—Body temperature increased—Vincristine—lymphatic system cancer	0.00031	0.000646	CcSEcCtD
Nilotinib—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000309	0.000642	CcSEcCtD
Nilotinib—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000306	0.000636	CcSEcCtD
Nilotinib—Urticaria—Mitoxantrone—lymphatic system cancer	0.000304	0.000632	CcSEcCtD
Nilotinib—Hypersensitivity—Carmustine—lymphatic system cancer	0.000303	0.00063	CcSEcCtD
Nilotinib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000302	0.000629	CcSEcCtD
Nilotinib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000302	0.000629	CcSEcCtD
Nilotinib—Pneumonia—Methotrexate—lymphatic system cancer	0.000301	0.000625	CcSEcCtD
Nilotinib—Vomiting—Bleomycin—lymphatic system cancer	0.0003	0.000623	CcSEcCtD
Nilotinib—Infestation—Methotrexate—lymphatic system cancer	0.000299	0.000621	CcSEcCtD
Nilotinib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000299	0.000621	CcSEcCtD
Nilotinib—Rash—Bleomycin—lymphatic system cancer	0.000297	0.000618	CcSEcCtD
Nilotinib—Dermatitis—Bleomycin—lymphatic system cancer	0.000297	0.000617	CcSEcCtD
Nilotinib—Asthenia—Carmustine—lymphatic system cancer	0.000295	0.000614	CcSEcCtD
Nilotinib—Renal failure—Methotrexate—lymphatic system cancer	0.000294	0.000611	CcSEcCtD
Nilotinib—Stomatitis—Methotrexate—lymphatic system cancer	0.000291	0.000606	CcSEcCtD
Nilotinib—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00029	0.000604	CcSEcCtD
Nilotinib—Hypersensitivity—Vincristine—lymphatic system cancer	0.000289	0.000602	CcSEcCtD
Nilotinib—Haematuria—Methotrexate—lymphatic system cancer	0.000285	0.000592	CcSEcCtD
Nilotinib—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000283	0.000588	CcSEcCtD
Nilotinib—Epistaxis—Methotrexate—lymphatic system cancer	0.000282	0.000586	CcSEcCtD
Nilotinib—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000282	0.000586	CcSEcCtD
Nilotinib—Asthenia—Vincristine—lymphatic system cancer	0.000282	0.000586	CcSEcCtD
Nilotinib—Diarrhoea—Carmustine—lymphatic system cancer	0.000281	0.000585	CcSEcCtD
Nilotinib—Nausea—Bleomycin—lymphatic system cancer	0.00028	0.000582	CcSEcCtD
Nilotinib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000274	0.000571	CcSEcCtD
Nilotinib—MAPK8—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000272	0.0494	CbGpPWpGaD
Nilotinib—BLK—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000272	0.0494	CbGpPWpGaD
Nilotinib—Dizziness—Carmustine—lymphatic system cancer	0.000272	0.000566	CcSEcCtD
Nilotinib—Haemoglobin—Methotrexate—lymphatic system cancer	0.00027	0.000561	CcSEcCtD
Nilotinib—Diarrhoea—Vincristine—lymphatic system cancer	0.000269	0.000559	CcSEcCtD
Nilotinib—Hepatitis—Methotrexate—lymphatic system cancer	0.000268	0.000558	CcSEcCtD
Nilotinib—Haemorrhage—Methotrexate—lymphatic system cancer	0.000268	0.000558	CcSEcCtD
Nilotinib—EPHA2—Direct p53 effectors—BCL6—lymphatic system cancer	0.000267	0.0484	CbGpPWpGaD
Nilotinib—Pharyngitis—Methotrexate—lymphatic system cancer	0.000266	0.000554	CcSEcCtD
Nilotinib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000265	0.000551	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—lymphatic system cancer	0.000263	0.000547	CcSEcCtD
Nilotinib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000262	0.000544	CcSEcCtD
Nilotinib—Vomiting—Carmustine—lymphatic system cancer	0.000262	0.000544	CcSEcCtD
Nilotinib—Dizziness—Vincristine—lymphatic system cancer	0.00026	0.00054	CcSEcCtD
Nilotinib—Rash—Carmustine—lymphatic system cancer	0.000259	0.000539	CcSEcCtD
Nilotinib—Dermatitis—Carmustine—lymphatic system cancer	0.000259	0.000539	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—lymphatic system cancer	0.000258	0.000538	CcSEcCtD
Nilotinib—Headache—Carmustine—lymphatic system cancer	0.000258	0.000536	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000254	0.000527	CcSEcCtD
Nilotinib—MAPK8—Circadian rythm related genes—PROX1—lymphatic system cancer	0.000251	0.0455	CbGpPWpGaD
Nilotinib—Eye disorder—Methotrexate—lymphatic system cancer	0.000251	0.000521	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—lymphatic system cancer	0.00025	0.00052	CcSEcCtD
Nilotinib—Vomiting—Vincristine—lymphatic system cancer	0.00025	0.000519	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000249	0.000518	CcSEcCtD
Nilotinib—MAPK8—DNA Damage Response (only ATM dependent)—BCL6—lymphatic system cancer	0.000248	0.045	CbGpPWpGaD
Nilotinib—Rash—Vincristine—lymphatic system cancer	0.000248	0.000515	CcSEcCtD
Nilotinib—Dermatitis—Vincristine—lymphatic system cancer	0.000247	0.000514	CcSEcCtD
Nilotinib—Headache—Vincristine—lymphatic system cancer	0.000246	0.000512	CcSEcCtD
Nilotinib—Nausea—Carmustine—lymphatic system cancer	0.000244	0.000508	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—lymphatic system cancer	0.000243	0.000506	CcSEcCtD
Nilotinib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000243	0.000506	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—lymphatic system cancer	0.000242	0.000504	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000242	0.000503	CcSEcCtD
Nilotinib—Rash—Mitoxantrone—lymphatic system cancer	0.000241	0.000501	CcSEcCtD
Nilotinib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000241	0.000501	CcSEcCtD
Nilotinib—Chills—Methotrexate—lymphatic system cancer	0.000241	0.0005	CcSEcCtD
Nilotinib—Headache—Mitoxantrone—lymphatic system cancer	0.00024	0.000498	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—lymphatic system cancer	0.000237	0.000493	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—lymphatic system cancer	0.000235	0.000489	CcSEcCtD
Nilotinib—Erythema—Methotrexate—lymphatic system cancer	0.000233	0.000486	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—lymphatic system cancer	0.000233	0.000486	CcSEcCtD
Nilotinib—Nausea—Vincristine—lymphatic system cancer	0.000233	0.000485	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000229	0.000475	CcSEcCtD
Nilotinib—Nausea—Mitoxantrone—lymphatic system cancer	0.000227	0.000472	CcSEcCtD
Nilotinib—Back pain—Methotrexate—lymphatic system cancer	0.000226	0.00047	CcSEcCtD
Nilotinib—MAPK14—IL4-mediated signaling events—BCL6—lymphatic system cancer	0.000222	0.0402	CbGpPWpGaD
Nilotinib—CA9—HIF-1-alpha transcription factor network—NPM1—lymphatic system cancer	0.000221	0.0401	CbGpPWpGaD
Nilotinib—Vision blurred—Methotrexate—lymphatic system cancer	0.00022	0.000458	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000217	0.000451	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—lymphatic system cancer	0.000216	0.000449	CcSEcCtD
Nilotinib—BRAF—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000215	0.039	CbGpPWpGaD
Nilotinib—Malaise—Methotrexate—lymphatic system cancer	0.000211	0.000438	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—lymphatic system cancer	0.00021	0.000436	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—lymphatic system cancer	0.000209	0.000435	CcSEcCtD
Nilotinib—Cough—Methotrexate—lymphatic system cancer	0.000204	0.000424	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—lymphatic system cancer	0.000199	0.000413	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—lymphatic system cancer	0.000199	0.000413	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—lymphatic system cancer	0.000199	0.000413	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000197	0.000411	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—lymphatic system cancer	0.000196	0.000408	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—lymphatic system cancer	0.000192	0.0004	CcSEcCtD
Nilotinib—Infection—Methotrexate—lymphatic system cancer	0.000189	0.000394	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000187	0.000389	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000187	0.000388	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—lymphatic system cancer	0.000185	0.000385	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000184	0.000383	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—lymphatic system cancer	0.000182	0.000378	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—lymphatic system cancer	0.000178	0.00037	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000174	0.000361	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—lymphatic system cancer	0.000172	0.000358	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—lymphatic system cancer	0.000171	0.000356	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—lymphatic system cancer	0.00017	0.000353	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—lymphatic system cancer	0.000168	0.000349	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—lymphatic system cancer	0.000166	0.000344	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000165	0.000342	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—lymphatic system cancer	0.000164	0.000342	CcSEcCtD
Nilotinib—LYN—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000163	0.0296	CbGpPWpGaD
Nilotinib—Pain—Methotrexate—lymphatic system cancer	0.000163	0.000339	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000157	0.000327	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000156	0.000324	CcSEcCtD
Nilotinib—MAPK14—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000155	0.0281	CbGpPWpGaD
Nilotinib—HCK—Host Interactions of HIV factors—NPM1—lymphatic system cancer	0.000154	0.028	CbGpPWpGaD
Nilotinib—Urticaria—Methotrexate—lymphatic system cancer	0.000151	0.000315	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—lymphatic system cancer	0.000151	0.000313	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—lymphatic system cancer	0.000151	0.000313	CcSEcCtD
Nilotinib—ABL1—DNA Damage Response (only ATM dependent)—BCL6—lymphatic system cancer	0.000148	0.0269	CbGpPWpGaD
Nilotinib—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00014	0.000292	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—lymphatic system cancer	0.000137	0.000284	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—lymphatic system cancer	0.000135	0.00028	CcSEcCtD
Nilotinib—LCK—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000134	0.0243	CbGpPWpGaD
Nilotinib—Diarrhoea—Methotrexate—lymphatic system cancer	0.00013	0.000271	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—lymphatic system cancer	0.000126	0.000262	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—lymphatic system cancer	0.000121	0.000252	CcSEcCtD
Nilotinib—Rash—Methotrexate—lymphatic system cancer	0.00012	0.00025	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—lymphatic system cancer	0.00012	0.00025	CcSEcCtD
Nilotinib—Headache—Methotrexate—lymphatic system cancer	0.000119	0.000248	CcSEcCtD
Nilotinib—Nausea—Methotrexate—lymphatic system cancer	0.000113	0.000235	CcSEcCtD
Nilotinib—ABCG2—HIF-1-alpha transcription factor network—NPM1—lymphatic system cancer	0.000112	0.0203	CbGpPWpGaD
Nilotinib—HCK—HIV Infection—NPM1—lymphatic system cancer	0.0001	0.0182	CbGpPWpGaD
Nilotinib—LCK—Host Interactions of HIV factors—NPM1—lymphatic system cancer	6.87e-05	0.0125	CbGpPWpGaD
Nilotinib—ABCB1—HIF-1-alpha transcription factor network—NPM1—lymphatic system cancer	6.04e-05	0.0109	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—RRP8—lymphatic system cancer	4.98e-05	0.00904	CbGpPWpGaD
Nilotinib—LCK—HIV Infection—NPM1—lymphatic system cancer	4.46e-05	0.0081	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—RRP8—lymphatic system cancer	3.56e-05	0.00645	CbGpPWpGaD
Nilotinib—HCK—Disease—NPM1—lymphatic system cancer	2.46e-05	0.00445	CbGpPWpGaD
Nilotinib—BRAF—Disease—NPM1—lymphatic system cancer	1.76e-05	0.00318	CbGpPWpGaD
Nilotinib—KIT—Disease—NPM1—lymphatic system cancer	1.6e-05	0.0029	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NPM1—lymphatic system cancer	1.51e-05	0.00274	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NPM1—lymphatic system cancer	1.36e-05	0.00247	CbGpPWpGaD
Nilotinib—LCK—Disease—NPM1—lymphatic system cancer	1.09e-05	0.00198	CbGpPWpGaD
